jueves, 12 de octubre de 2017

Cancer Information Highlights, October 12, 2017

National Cancer Institute sent this bulletin at 10/12/2017 08:47 AM EDT

Cancer Information Highlights

From the National Cancer Institute

Updating you about cancer causes, prevention, screening, treatment, coping, and more

New from NCI
TMIST Breast Screening Trial
		TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography: standard digital mammography (2-D) and a newer technology called tomosynthesis mammography (3-D).
Breast Changes and Conditions
		This page can help you learn about symptoms during your lifetime that are not cancer, as well as follow-up tests used to diagnose breast conditions and treatments for specific breast conditions.
HIV Infection and Cancer Risk This fact sheet has been completely revised and includes cancers that pose an increased risk to people infected with HIV, risk estimates, and updated references.
Timing and Sequence Are Critical for Combination Immunotherapy In a study in mice, two immune checkpoint inhibitors given at the same time did not stop breast cancer growth. The combination was more effective and safer if the two inhibitors were given in a specific sequence.
New Approval for Acute Myeloid Leukemia FDA has approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML) that expresses a protein called CD33.
PDQ Summary Updates
Laryngeal Cancer Treatment Our PDQ summary on laryngeal cancer has updated information on treatment options and the treatments that are used for the different stages of the cancer.
Male Breast Cancer Treatment We’ve revised our PDQ summary on male breast cancer with updated information about risk factors and the treatment of metastatic disease.
Drug Information Updates
New Drug for Leukemia We’ve added a drug summary for daunorubicin and cytarabine liposome. It was recently approved by FDA to treat certain types of acute myeloid leukemia.
New Drug for Lymphoma We’ve added a new drug summary for copanlisib hydrochloride. It was recently approved by FDA to treat follicular lymphoma, which is a type of non-Hodgkin lymphoma.
Nivolumab to Treat Liver Cancer We’ve updated our drug information summary on nivolumab to include the recent FDA approval for the treatment of hepatocellular carcinoma, which is a type of liver cancer.
Pembrolizumab for Gastric (Stomach) Cancer Our drug summary on pembrolizumab now includes treatment of cancer of the stomach and gastroesophageal junction. It was approved by FDA to treat certain patients whose disease got worse with other treatment.

Also of Interest
Breast Cancer October is National Breast Cancer Awareness Month. Visit our Breast Cancer gateway page to learn about all our resources on breast cancer treatment, screening, causes and prevention, and statistics.
Cancer Risk Factors—Hormones Estrogens are known to cause cancer in humans. Although these hormones have essential roles in both women and men, they have also been linked with an increased risk of certain cancers.
Mammograms This fact sheet explains the role of mammograms in screening for breast cancer. Learn about the types of mammograms, potential benefits and harms of breast cancer screening, and newer technologies being used in breast cancer screening.